Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2015-05-31
2017-11-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Only the cartilaginous part of the ET is accessible for treatment procedures. We also know that 20% of the patients dilated do not respond to dilation, and relapse of middle ear disease occurs (2). At present, no diagnostic procedure can distinguish between later responders and non-responders to dilation. Therefore, level diagnostics of obstruction and possibly identification of other discriminating parameters are important. Computer tomography (CT) is considered necessary before any type of tube intervention, mainly to exclude obstruction in the bony part of the tube or identification of any other pathoanatomical condition to contraindicate balloon dilatation. Visualisation of obstructions in the cartilaginous part is not possible with today's methods. Nor does the method provide any information on tube function.
There is a need for better diagnostic imaging of the ET. In this project we plan to develop a method for contrast medium application to the ET via the middle ear followed by CT imaging. The purpose is to tell whether the ET is open or on which level it is obstructed. So far some publications have showed that contrast media can pass through the ET (6,7,8), but no systematic trials have been published, clarifying the potential of the method.
We have recently conducted studies on temporal bone specimens from human cadavers and on 8 living rabbits. Results from these studies are not yet published, but our hypotheses are supported that the method for ET visualisation is feasible, safe, and that contrast media passes unhindered through a normal ET after application in the middle ear (6,7,8).
Hence the next step of the trial is to explore whether the method provides new information in human subjects with and without tube dysfunction.
Hypotheses Contrast medium applied in the middle ear passes through the ET and is visualised in the epipharynx in the following CT examination of the temporal bone in individuals with healthy middle ears and ET.
Contrast media applied in the middle ear does not pass through the entire ET and is not visualised in the epipharynx in the following CT examination of the temporal bone in individuals in the patient group.
It is possible to identify a highest level of obstruction after contrast media application in the middle ear based on visual identification of the lowest visible level of contrast medium in the ET in the following CT examination of the temporal bone in the patient group.
Level of obstruction of the ET predicts outcome of ET balloon dilation.
Material One fifth of chronic patients with otitis media with effusion (OME) have no beneficial effect of balloon dilation (2). We hypothesize that contrast media will not pass through the bony part of the ET in a majority of these patients, while it does in a majority of the patients experiencing successful relief of disease after balloon dilation. Variation is not known, but is presumed not to exceed 20%. Sample size calculation is not straight-forward in this case, handling dichotomous variables. Power calculation indicates a needed number of 80 individuals in the patient group to have a power of at least 80% for the detection of difference between these 2 groups with an alpha level of 5% with two-sided tests. Additionally, we include 15 controls with presumed healthy middle ears and ET to verify significantly better contrast media passage to epipharynx in these individuals than in the group of patients with chronic OME, based on similar power calculation.
Recruitment of this number to undergo a CT examination with contrast carefully administered through the tympanostomy tube will be done during a clinically indicated and planned CT to avoid excess radiation dose and additional visits to the hospital for the patients.
Mb Meniere patients are occasionally treated with tympanostomy tubes, although they do not have middle ear pathology. This patient group also routinely undergoes CT-examination of the temporal bone. Hence we plan to include 10 patients with mb Meniere and tympanostomy tubes to be examined with a similar contrast medium CT protocol as described above as a healthy control group.
Method Out patients referred to the Ear, nose and throat (ENT)-clinic for OME will be offered to be part of the study, given that they qualify according to the inclusion and exclusion criteria. All patients will be given written information and a consensus form.
At their first visit, the ENT- surgeon will control the status of the eardrum and middle ear by otomicroscopy. The extent of pneumatisation / atelectasis and fluid in the middle ear will be evaluated in addition to the state and position of the tympanic membrane. With a nasal endoscope the condition of Rosenmullers fossa and the function of torus tubarius will be examined. The latter is controlled by asking the patient to equalize pressure while the scope is in the nasopharynx, and the opening of the torus can be seen. The patients and controls are interviewed structurally for symptoms related to middle ear and temporal bone disease.
Included patients without a tympanostomy tube will be given one the same day as the clinical examination. The patients who are not treated with nasal corticosteroids will be prescribed them for use up until the first control.
CT will be performed after 3-4 weeks. At the CT-lab an ENT-surgeon will drip 2 ml iodixanol contrast medium diluted with saline (NaCl) to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After turning the head to a neutral position and a delay of 10 minutes the CT examination will be conducted using 200 milliampere (mA) and 120 kilo volt (kV).
Reconstructions will be made from the raw material. In addition to axial and coronal reconstructions, images series will be reconstructed in an oblique coronal image plane.
The physicist will contribute to achieve the best possible protocol. As an example it is possible to use different kV values while keeping the dose parameters (CTDIw) on the same level as for the existing temporal bone protocol. By allowing the mAs value to change, we will be able to decide on the optimal kV level for this study, without exposing some of the patients to higher radiation dose.
The physicist will also be involved in the optimisation of the reconstruction of the images of ET. The images will be reconstructed with different filters and degrees of iterative reconstruction. Using radiologists as observers, the optimal reconstruction settings for the Eustachian tube will be selected. The physicist will also calculate organ doses and effective dose for the patients.
All patients included in the study will be treated with balloon dilation in general anaesthesia, 3 - 4 weeks after the CT procedure. The ENT surgeon will be blinded to the result from the contrast media part of the CT examination. In relation to the hospital stay for balloon dilation patients will be repeatedly examined and interviewed similarly to the examination at inclusion.
Follow-up is conducted 3 months and 6 months after balloon dilatation with renewed clinical examination and interview, according to the presently established routine follow-up.
Parameters to be noted from the different time points are CT findings including contrast media passage, clinical and biochemical signs on inflammation and/or infection, symptoms related to middle ear or temporal bone disease and/or general infection, and clinical result from ET balloon dilation finally dividing the patient group into responders or non-responders from dilation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iodixanol to the Eustachian tube
Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
Iodixanol to the Eustachian tube
Application of iodixanol to the middle ear for imaging of the ET.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iodixanol to the Eustachian tube
Application of iodixanol to the middle ear for imaging of the ET.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Benedicte Falkenberg-Jensen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Petter Berg, MD, PhD
Role: STUDY_DIRECTOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo UH
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET31068
Identifier Type: -
Identifier Source: org_study_id